⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29257635 | 0.97 | EPHX1 (0.61) | — | |
| SCHEMBL29257633 | 0.97 | EPHX1 (0.61) | — | |
| SCHEMBL7041700 | 0.97 | EPHX1 (0.61) | — | |
| SCHEMBL19527248 | 0.97 | EPHX1 (0.61) | — | |
| SCHEMBL20036343 | 0.97 | EPHX1 (0.61) | — | |
| SCHEMBL1899064 | 0.92 | — | — | |
| SCHEMBL1895673 | 0.79 | — | — | |
| SCHEMBL19775445 | 0.77 | ADH1B (0.35) | — | |
| SCHEMBL9391 | 0.74 | — | — | |
| SCHEMBL28467876 | 0.74 | EPHX1 (0.67) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2550257-B1 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES | LEAD DISCOVERY CENTER GMBH (DE) | 2016-12-21 | — | — | EP | claimed |
| US-20130079345-A1 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-28 | — | — | US | claimed |
| EP-2550257-A1 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES | Lead Discovery Center GmbH (DE) | 2013-01-30 | — | — | EP | claimed |
| WO-2011116951-A1 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES | LEAD DISCOVERY CENTER GMBH (DE) | 2011-09-29 | — | — | WO | claimed |
| CN-107635970-B | Benzimidazolone and benzothiazolone compounds and their use as AMPA receptor modulators | 詹森药业有限公司 | 2021-03-12 | — | — | CN | disclosed |
| EP-3288936-B1 | BENZIMIDAZOLONE AND BENZOTHIAZOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-06 | — | — | EP | disclosed |
| US-10611730-B2 | Benzimidazolone and benzothiazolone compounds and their use as AMPA receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-07 | — | — | US | disclosed |
| US-20190092735-A1 | BENZIMIDAZOLONE AND BENZOTHIAZOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-03-28 | — | — | US | disclosed |
| US-10051861-B2 | N-arylamidine-substituted trifluoroethyl sulfide derivatives as acaricides and insecticides | BAYER CROPSCIENCE AG (DE) | 2018-08-21 | — | — | US | disclosed |
| EP-3288936-A1 | BENZIMIDAZOLONE AND BENZOTHIAZOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2018-03-07 | — | — | EP | disclosed |
| US-9642363-B2 | N-arylamidine-substituted trifluoroethyl sulfide derivatives as acaricides and insecticides | BAYER CROPSCIENCE AG (DE) | 2017-05-09 | — | — | US | disclosed |
| US-20170057914-A1 | N-ARYLAMIDINE-SUBSTITUTED TRIFLUOROETHYL SULFIDE DERIVATIVES AS ACARICIDES AND INSECTICIDES | BAYER CROPSCIENCE AG | 2017-03-02 | — | — | US | disclosed |
| US-20140287454-A1 | SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-09-25 | — | — | US | disclosed |
| EP-2748331-A1 | SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS | Lead Discovery Center GmbH (DE) | 2014-07-02 | — | — | EP | disclosed |
| EP-2747755-A1 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA | Lead Discovery Center GmbH (DE) | 2014-07-02 | — | — | EP | disclosed |
| US-20130079345-A1 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-28 | — | — | US | disclosed |
| WO-2013026874-A1 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA | LEAD DISCOVERY CENTER GMBH (DE) | 2013-02-28 | — | — | WO | disclosed |
| WO-2013026890-A1 | SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2013-02-28 | — | — | WO | disclosed |
| EP-2562265-A1 | Susceptibility to selective CDK9 inhibitors | Lead Discovery Center GmbH (DE) | 2013-02-27 | — | — | EP | disclosed |
| EP-2561867-A1 | CDK9 inhibitors in the treatment of midline carcinoma | Lead Discovery Center GmbH (DE) | 2013-02-27 | — | — | EP | disclosed |